Advancement of the third generation of antihistamines

Pediatric Asthma, Allergy and Immunology

Volumn 13, Issue 4, 1999, Pages 163-168

  Handley, Dean A ^a  

^a SUNOVION PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; ASTEMIZOLE; CETIRIZINE; CIMETIDINE; DESLORATADINE; ERYTHROMYCIN; FEXOFENADINE; HISTAMINE H1 RECEPTOR; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR; HISTAMINE H2 RECEPTOR ANTAGONIST; KETOCONAZOLE; LEVOCETIRIZINE; LORATADINE; NORASTEMIZOLE; POTASSIUM CHANNEL; RANITIDINE; TERFENADINE; UNCLASSIFIED DRUG;

ALLERGY; ANTICHOLINERGIC EFFECT; DROWSINESS; DRUG DOSAGE FORM; DRUG METABOLISM; HEART ARRHYTHMIA; HUMAN; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; TORSADE DES POINTES; XEROSTOMIA;

EID: 0033494989     PISSN: 08831874     EISSN: None     Source Type: Journal    
DOI: 10.1089/pai.1999.13.163     Document Type: Review

References (19)

1. Adelsberg BR. Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 1997; 157:494-500.
2. Woosely RL. Cardiac actions of antihistamines. Ann Rev Pharmacol Toxicol 1996; 36:233-52.
3. Dale H, Laidlaw P. Histamine acts as a bronchoconstnctor in allergic guinea pigs. J Physiol 1910; 41:318-14.
4. 1-receptor-antagonist drugs. N Engl J Med 1994; 330:1663-70.
5. Kaliner MA. Nonsedating antihistamines: Pharmacology, clinical efficacy and adverse effects. Am Fam Physician 1992; 45:1337-42.
6. 2-receptors. Nature 1972; 236:385-90.
7. 1-receptor antagonists Clin Exp Allergy 1996; 26:1092-97.
8. + channel cloned from human heart. Mol Pharmacol 1993; 44:1240-45.
9. Garteiz DA, Hoch RH, Okerholm RA. Pharmacokinetic and biotransformational studies of terfenadine in man. Drug Res 1982; 32:1185-90.
10. Yun CH, Okerholm RA, Guengerich FP. Oxidation of the antihistamine drug terfenadine in human liver microsomes: Role of cytochrome P-450 CYP3A4 in N-dealkylation and C-hydroxylation. Drug Metab Dispos 1993; 21:403-9.
11. Hoechst Marion Roussel, Inc, and Baker Norton Pharmaceuticals, Inc. Terfenadine: Proposal to withdraw approval of two new drug applications and one abbreviated new drug application; opportunity for a hearing. Federal Register 1997; 62:1889-92.
12. Handley DA, Hong Y, Bakale R, Senanayake C. Norastemizole. Drugs Future 1998; 23:966-69.
13. Physicians Desk Reference. Montvale, NJ: 1997, pp. 1189-90.
14. Handley DA, McCullough JR, Fang KQ, Wright SE, Smith ER. Comparative antihistamine effects of astemizole and a metabolite, norastemizole. Ann Allergy Asthma Immunol 1997; 78:144 (abstract).
15. Pinto YM, van Gelder IC, Heeringa M, Crijns HJGM QT lengthening and life-threatening arrhythmias associated with fexofenadine. Lancet 1999; 353:980-984.
16. Giraud T. QT lengthening and arrhythmias associated with fexofenadine. Lancet 1999; 353:2072-2074.
17. Handley DA, McCullough JR, Fang Y, Wright SE, Smith ER. Descarboethoxyloratadine, a metabolite of loratadine, is a superior antihistamine. Ann Allergy Asthma Immunol 1997; 78:143 (abstract).
18. Cardelus I, Anton F, Beleta J, Palacios JM. Anticholinergic effects of desloratadine, the major metabolite of loratadine, in rabbit and guinea-pig iris smooth muscle. Eur J Pharmacol 1999; 374:249-54.
19. Brannan MD, Reidenberg P, Radwanaski E. Loratadine administered concomitantly with erythromycin: pharmacokinetic and electrocardiographic evaluations. Clin Pharmacol Ther 1995; 58:269-78.